NCT02054520View on ClinicalTrials.gov

Immunotherapy Study for Patients With Stage IV Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 5, 2018

Study Completion Date

January 5, 2021

Conditions
Stage IV MelanomaMetastatic Melanoma
Interventions
DRUG

HyperAcute®-Melanoma (HAM) Immunotherapy

DRUG

Ipilimumab

DRUG

Pembrolizumab

DRUG

Nivolumab

Trial Locations (5)

27157

Wake Forest Baptist Health, Winston-Salem

37920

University of Tennessee Medical Center, Knoxville

52242

University of Iowa Hospitals and Clinics, Iowa City

60714

Oncology Specialists, Niles

Unknown

University of Kansas Cancer Center, Westwood

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT02054520 - Immunotherapy Study for Patients With Stage IV Melanoma | Biotech Hunter | Biotech Hunter